--Apple World Wide Developers Conference Set for Week of June 9-November 2024-www.financetom.com

--Apple World Wide Developers Conference Set for Week of June 9

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Apple World Wide Developers Conference Set for Week of June 9

Mar 25, 2025 11:10 AM

01:55 PM EDT, 03/25/2025 (MT Newswires) --

Price: 222.84, Change: +2.11, Percent Change: +0.96

Previous page： --Simpson Manufacturing Keeps Quarterly Dividend at $0.28 a Share, Payable Jan. 23 to Shareholders of Record Jan. 2 Next page： Southwest, American Airlines Beat Quarterly Views; Southwest Reaches Deal With Elliott

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Simpson Manufacturing Keeps Quarterly Dividend at $0.28 a Share, Payable Jan. 23 to Shareholders of Record Jan. 2

Oct 24, 2024

10:34 AM EDT, 10/24/2024 (MT Newswires) -- Price: 178.43, Change: +1.95, Percent Change: +1.10 ...

Southwest, American Airlines Beat Quarterly Views; Southwest Reaches Deal With Elliott

Oct 24, 2024

10:32 AM EDT, 10/24/2024 (MT Newswires) -- Southwest Airlines ( LUV ) and American Airlines ( AAL ) reported better-than-expected third-quarter results, while Southwest ( LUV ) said it reached a cooperation agreement with activist investor Elliott Investment Management. Southwest's ( LUV ) adjusted earnings declined to $0.15 a share for the September quarter from $0.38 the year before, but...

--Ardagh Metal Packaging Maintains Quarterly Dividend at $0.10 a Share, Payable Dec. 19 to Shareholders of Record Dec. 5

Oct 24, 2024

10:32 AM EDT, 10/24/2024 (MT Newswires) -- Price: 4.00, Change: -0.19, Percent Change: -4.53 ...

Zai Lab's Lung Cancer Treatment Candidate Shows 'Promising' Results in Trial; Shares Rise

Oct 24, 2024

10:32 AM EDT, 10/24/2024 (MT Newswires) -- Zai Lab ( ZLAB ) said Thursday that results from the ongoing phase 1a/1b trial of ZL-1310 in people with extensive-stage small cell lung cancer following at least one previous platinum-based chemotherapy treatment showed promising objective response rates and safety profile. The objective response rate was 74% in all tested dose levels of...